Novo Nordisk starts crucial trial of obesity tablet

While Novo Nordisk struggles to meet the demand for its injection-based treatment Wegovy in the US, the pharmaceutical company has started a phase IIIa trial of semaglutide as a tablet-based treatment for obesity, aiming for similar weight loss results.

Photo: Stine Tidsvilde

On Monday, Novo Nordisk initiated a global phase IIIa trial of semaglutide in tablet form, as a treatment for obesity, the pharmaceutical company confirms to MedWatch.

The phase IIIa trial, called Oasis 1, comes at a time when Novo Nordisk is already experiencing huge US demand for its newly-launched obesity drug Wegovy. In its own phase III trials, this drug demonstrated an average weight loss of 17-18 percent in participants without type 2 diabetes, and the two drugs are based on the same active ingredient, semaglutide - though Wegovy is administered via injection.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs